<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2017.61003</article-id><article-id pub-id-type="publisher-id">HJO-19945</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20170100000_30428055.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  增殖性糖尿病视网膜病变围手术期玻璃体腔内注射康柏西普的疗效研究
  Study on the Effect of Conbercept Intravitreal Injection for Proliferative Diabetic Retinopathy at Perioperative Period
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>梦丹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>靖</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>云霄</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>廷</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>哲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>盼盼</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>全</surname><given-names>威</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>青岛市妇女儿童医院，眼科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院，东区感染科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院，眼科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>20</day><month>03</month><year>2017</year></pub-date><volume>06</volume><issue>01</issue><fpage>12</fpage><lpage>18</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：对比观察单行玻璃体切除术(Pars Plana vitrectomy, PPV)与玻璃体腔内注射康柏西普联合玻璃体切除术治疗增殖性糖尿病视网膜病变(Proliferative diabetic retinopathy, PDR)的临床效果。方法：选取我院2014-12/2015-12收治的PDR患者23例26眼，随机分为两组。单行PPV治疗的患者为对照组(11例12眼)，在行PPV术前行康柏西普玻璃体腔内注射的患者为试验组(12例14眼)。术后随访1年，观察两组患者手术情况及治疗效果。结果：试验组的平均手术时间、术中严重出血率均少于对照组。两组患者术前CMT、BCVA差异无统计学意义，术后试验组明显优于对照组，且差异具有统计学意义。结论：行PPV前玻璃体腔内注射康柏西普可以有效的缩短手术时间，减少术中出血，降低医源性裂孔的发生率，减轻黄斑水肿，提高患者的最佳矫正视力。
    AIM: To compare the effects of pars plana vitrectomy (PPV) with or without conbercept intravitreal injection of proliferative diabetic retinopathy (PDR). METHODS: 23 patients (26 eyes) with PDR in our hospital from December 2014 to December 2015 were recruited, and were randomly divided into two groups. 11 cases (12 eyes) in control group were received single vitrectomy. In ex-perimental group, 12 cases (14 eyes) were injected by drug therapy of conbercept and received vitrectomy. In the postoperative follow-up of 1 year, the general situation of operation and thera-peutic effect between the two groups were analyzed. RESULTS: The average operation time, bleeding during operation of the experimental group were lower than that of the control group; they were significantly different. There was no statistically significant difference between two groups on CMT &amp; BCVA before operation, but the experimental group had better effect than control group at 4mo. CONCLUSION: Intravitreal injection of conbercept before vitrectomy can decrease the operation time, reduce active neovascularization, minimize the incidence of intraoperative haemorrhage and iatrogenic retinal breaks incidence, alleviate macular edema and improve BCVA of patients in the treatment of PDR. 
  
 
</p></abstract><kwd-group><kwd>增殖性糖尿病视网膜病变，康柏西普，玻璃体切除术, Proliferative Diabetic Retinopathy</kwd><kwd> Conbercept</kwd><kwd> Pars Plana Vitrectomy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>增殖性糖尿病视网膜病变围手术期玻璃体腔内注射康柏西普的疗效研究<sup> </sup></title><p>于梦丹<sup>1</sup>，姜 涛<sup>1*</sup>，姜 靖<sup>2</sup>，王云霄<sup>1</sup>，李 廷<sup>3</sup>，孙 哲<sup>1</sup>，郑盼盼<sup>1</sup>，全 威<sup>1</sup></p><p><sup>1</sup>青岛大学附属医院，眼科，山东 青岛</p><p><sup>2</sup>青岛大学附属医院，东区感染科，山东 青岛</p><p><sup>3</sup>青岛市妇女儿童医院，眼科，山东 青岛</p><disp-formula id="hanspub.19945-formula1"><graphic xlink:href="http://html.hanspub.org/file/3-2230134x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年3月3日；录用日期：2017年3月20日；发布日期：2017年3月23日</p><disp-formula id="hanspub.19945-formula2"><graphic xlink:href="http://html.hanspub.org/file/3-2230134x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：对比观察单行玻璃体切除术(Pars Plana vitrectomy, PPV)与玻璃体腔内注射康柏西普联合玻璃体切除术治疗增殖性糖尿病视网膜病变(Proliferative diabetic retinopathy, PDR)的临床效果。方法：选取我院2014-12/2015-12收治的PDR患者23例26眼，随机分为两组。单行PPV治疗的患者为对照组(11例12眼)，在行PPV术前行康柏西普玻璃体腔内注射的患者为试验组(12例14眼)。术后随访1年，观察两组患者手术情况及治疗效果。结果：试验组的平均手术时间、术中严重出血率均少于对照组。两组患者术前CMT、BCVA差异无统计学意义，术后试验组明显优于对照组，且差异具有统计学意义。结论：行PPV前玻璃体腔内注射康柏西普可以有效的缩短手术时间，减少术中出血，降低医源性裂孔的发生率，减轻黄斑水肿，提高患者的最佳矫正视力。</p><p>关键词 :增殖性糖尿病视网膜病变，康柏西普，玻璃体切除术</p><disp-formula id="hanspub.19945-formula3"><graphic xlink:href="http://html.hanspub.org/file/3-2230134x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>增殖性糖尿病视网膜病变(Proliferative diabetic retinopathy, PDR)是导致糖尿病患者视力丧失的重要原因。当出现严重的玻璃体积血(vitreous hemorrhage, VH)、牵拉性视网膜脱离(tractional retinal detachment, TRD)、视网膜前膜(epi-retinal membrane, ERM)时，须行平坦部玻璃体切除术(pars plana vitrectomy, PPV)，清除玻璃体积血，剥除增殖膜，解除对视网膜的牵引并复位视网膜。但对于多数PDR患者，增殖性纤维血管膜与视网膜粘连紧密，术中剥膜极易发生医源性裂孔及大量出血，术中视野差、手术时间长、手术难度大，加之PPV术后并发症影响手术效果，最终患者视力往往得不到提高。研究表明，PDR患者眼内尤其是玻璃体内血管内皮生长因子(vascular endothelial growth factor, VEGF)含量大幅增高，其在PDR的发展恶化中起重要作用。抗VEGF治疗可有效阻止血管渗漏和新生血管的形成，减少PPV术中及术后并发症 [<xref ref-type="bibr" rid="hanspub.19945-ref1">1</xref>] 。本文中我们将比较两组患者手术难易程度、手术并发症及其疗效。</p></sec><sec id="s4"><title>2. 对象和方法</title><sec id="s4_1"><title>2.1. 对象</title><p>选取2014-12/2015-12我院收治的PDR患者23例26眼。其中单行PPV治疗的为对照组，康柏西普玻璃体腔内注射联合PPV的患者为试验组。患者纳入标准：(1) 经散瞳后眼底镜等检查确诊为增殖性糖尿病视网膜病变；(2) 视力明显下降；(3) 患者均签署PPV手术及康柏西普玻璃体腔内注射知情同意书；(4) 所有PPV手术及玻璃体腔注药均由同一手术医师完成。排除标准：(1) 存在其他眼部疾病；(2) 接受过激光治疗或存在其他眼部手术史；(3) 肝肾功能异常；(4) 存在心肌梗死、脑梗死、难以控制的高血压以及恶性肿瘤；(5) 妊娠或者哺乳期妇女。两组患者一般资料比较，差异无统计学意义(P &gt; 0.05)，具有可比性，见表1。</p></sec><sec id="s4_2"><title>2.2.方法</title><sec id="s4_2_1"><title>2.2.1.手术方法</title><p>(1) 康柏西普玻璃体腔注射</p><p>术前抗生素滴眼液预防感染，所有操作均按照无菌操作要求完成，患者取仰卧位，表面麻醉，常规消毒铺无菌巾，于颞下象限睫状体平坦部进针，注射康柏西普0.5 mg/0.05ml于玻璃体腔内，棉签压迫5min，观察无渗漏，涂抗生素眼膏包眼。次日观察术眼前后节情况，测眼压。术后抗生素滴眼液点术眼 qid，直至行PPV治疗。</p><p>(2) 玻璃体切除术</p><p>手术前后抗生素滴眼预防感染，所有操作均按照无菌操作要求完成，患者取仰卧位，常规消毒铺无菌巾，利多卡因+罗哌卡因混合液球后阻滞麻醉，做23G显微切口切除玻璃体，根据术中情况行视网膜切开、复位、剥增殖膜、激光光凝、气液交换、硅油填充等。</p></sec><sec id="s4_2_2"><title>2.2.2. 试验观察指标</title><p>记录两组患者手术前后 CFT、BCVA，手术时间，术中出血、医源性裂孔发生率，术后随访1年，记录4个月时CFT、BCVA及并发症的发生率。</p></sec><sec id="s4_2_3"><title>2.2.3. 统计分析</title><p>采用SPSS 17.0统计学软件进行统计学分析。两组患者年龄、病程、术前空腹血糖、手术时间以χ̅&#177;s表示，组间计量资料差异比较采用独立样本t检验，计数资料差异比较采用X<sup>2</sup>检验,以P&lt;0. 05 为差异有统计学意义。</p></sec></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 两组患者手术情况的比较</title><p>本研究中试验组患者玻璃体腔内注射康柏西普后至行玻璃体切除术之前的时间内，我们观察到患者虹膜新生血管明显消退，玻璃体积血较前减轻，眼底新生血管膜也有不同程度消退。手术时间方面，试验组与对照组的平均手术时间相比：(75.64 &#177; 18.73) min VS (95.36 &#177; 14.74) min，差异有显著统计学</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic data of two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >参数</th><th align="center" valign="middle" >试验组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >t/X<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >例数</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >眼数</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >平均年龄(<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/3-2230134x10_hanspub.png" xlink:type="simple"/></inline-formula>，岁)</td><td align="center" valign="middle" >57.05 &#177; 7.82</td><td align="center" valign="middle" >60.02 &#177; 7.24</td><td align="center" valign="middle" >−1.339<sup>*</sup></td><td align="center" valign="middle" >0.190</td></tr><tr><td align="center" valign="middle" >男性例数(例)</td><td align="center" valign="middle" >5 (41.7%)</td><td align="center" valign="middle" >5 (45.5%)</td><td align="center" valign="middle" >0.034<sup>#</sup></td><td align="center" valign="middle" >0.855</td></tr><tr><td align="center" valign="middle" >糖尿病类型</td><td align="center" valign="middle" >2型(100%)</td><td align="center" valign="middle" >2型(100%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >糖尿病病程(<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/3-2230134x11_hanspub.png" xlink:type="simple"/></inline-formula>，年)</td><td align="center" valign="middle" >14.27 &#177; 4.585</td><td align="center" valign="middle" >14.80 &#177; 4.940</td><td align="center" valign="middle" >−0.254<sup>*</sup></td><td align="center" valign="middle" >0.802</td></tr><tr><td align="center" valign="middle" >术前空腹血糖(<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/3-2230134x12_hanspub.png" xlink:type="simple"/></inline-formula>, mmol/L)</td><td align="center" valign="middle" >6.86 &#177; 3.04</td><td align="center" valign="middle" >6.42 &#177; 2.83</td><td align="center" valign="middle" >0.408*</td><td align="center" valign="middle" >0.686</td></tr></tbody></table></table-wrap><p>表1. 患者术前基本资料的比较</p><p>意义(t = −3.435, P = 0.001)。术中出现需要眼内电凝止血的严重、持续性出血眼数，试验组与对照组相比：2眼(14.3%) VS 7眼(58.3%)，差异有统计学意义(X<sup>2</sup> = 5.539, P = 0.019)。医源性裂孔发生率、硅油填充率、因复发玻璃体积血或视网膜脱离行2次手术率，试验组小于对照组，但差异并无统计学差异，填充硅油者均于术后3~6个月顺利取出硅油。随访期内因术眼白内障影响视力者均行白内障手术治疗。见表2。</p></sec><sec id="s5_2"><title>3.2. 两组患者手术前后CFT变化的比较</title><p>本研究中试验组术后4 mo时黄斑中心凹厚度为(214.91 &#177; 30.15) μm，与术前黄斑中心凹厚度(441.92 &#177; 146.92) μm相比较，差异具有显著统计学意义(t = 5.019, P = 0.000)。对照组术后4 mo时黄斑中心凹厚度为(318.92 &#177; 156.17) μm，与术前黄斑中心凹厚度(452.23 &#177; 159.62) μm相比较，差异同样具有统计学意义(t = 2.152, P = 0.042)。两组患者术前黄斑中心凹厚度比较，差异无统计学意义，而试验组术后4 mo时黄斑中心凹厚度小于对照组，且差异具有统计学意义(P = 0.041)。见表3。试验组患者A随访期间OCT见图1。</p></sec><sec id="s5_3"><title>3.3. 两组患者手术前后最佳矫正视力比较</title><p>本研究中视力采用ETDRS视力表测得，试验组术后4 mo时 BCVA 为(56.25 &#177; 22.90)，与术前(20.65 &#177; 26.53)相比较，字母数增加，差异具有显著统计学意义(t = −4.543，P = 0.000)。对照组术后4 mo时BCVA为(38.57 &#177; 24.72)，与术前(22.29 &#177; 21.78)相比较，字母数也有所增加。两组患者术前BCVA比较，差异无统计学意义(P = 0.851)，而试验组术后4 mo时BVCA大于对照组，且差异具有统计学意义(P = 0.040)。见表4。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>PDR往往出现玻璃体出血、纤维增殖及牵拉所致的黄斑移位、黄斑水肿、视网膜脱离等。目前，PPV依然是PDR治疗的主流方法。该手术旨在切除积血的玻璃体，剥除新生血管膜，解除其对视网膜的牵拉，</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The operation of two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >参数</th><th align="center" valign="middle" >试验组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >t/x<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >手术时间(<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/3-2230134x13_hanspub.png" xlink:type="simple"/></inline-formula>, min)</td><td align="center" valign="middle" >75.64 &#177; 18.73</td><td align="center" valign="middle" >95.36 &#177; 14.74</td><td align="center" valign="middle" >−3.435<sup>*</sup></td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >术中严重出血眼数</td><td align="center" valign="middle" >2 (14.3%)</td><td align="center" valign="middle" >7 (58.3%)</td><td align="center" valign="middle" >5.539<sup>#</sup></td><td align="center" valign="middle" >0.019</td></tr><tr><td align="center" valign="middle" >医源性裂孔眼数</td><td align="center" valign="middle" >3 (21.4%)</td><td align="center" valign="middle" >5 (41.7%)</td><td align="center" valign="middle" >1.242<sup>#</sup></td><td align="center" valign="middle" >0.265</td></tr><tr><td align="center" valign="middle" >硅油填充眼数</td><td align="center" valign="middle" >4 (28.6%)</td><td align="center" valign="middle" >8 (66.7%)</td><td align="center" valign="middle" >3.773<sup>#</sup></td><td align="center" valign="middle" >0.052</td></tr><tr><td align="center" valign="middle" >再次手术眼数</td><td align="center" valign="middle" >1 (7.1%)</td><td align="center" valign="middle" >2 (16.7%)</td><td align="center" valign="middle" >0.574<sup>#</sup></td><td align="center" valign="middle" >0.449</td></tr></tbody></table></table-wrap><p>表2. 患者手术情况的比较</p><p>注：*为t值；#为X<sup>2</sup>值。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The central foveal thickness of two groups before and after the operatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >眼数</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >452.23 &#177; 159.62</td><td align="center" valign="middle" >318.92 &#177; 156.17</td><td align="center" valign="middle" >2.152</td><td align="center" valign="middle" >0.042</td></tr><tr><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >441.92 &#177; 146.92</td><td align="center" valign="middle" >214.91 &#177; 30.15</td><td align="center" valign="middle" >5.019</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.168</td><td align="center" valign="middle" >2.168</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.868</td><td align="center" valign="middle" >0.041</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 两组患者手术前后黄斑中心凹厚度变化的比较<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/3-2230134x15_hanspub.png" xlink:type="simple"/></inline-formula></p><p>图1. 试验组患者A随访期间OCT</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The comparison of the best corrected visual acuity in the two groups before and after the operatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >眼数</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >20.65 &#177; 26.53</td><td align="center" valign="middle" >56.25 &#177; 22.90</td><td align="center" valign="middle" >−4.543</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >22.29 &#177; 21.78</td><td align="center" valign="middle" >38.57 &#177; 24.72</td><td align="center" valign="middle" >−1.850</td><td align="center" valign="middle" >0.076</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.190</td><td align="center" valign="middle" >2.145</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.851</td><td align="center" valign="middle" >0.040</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 两组患者手术前后最佳矫正视力的比较<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/3-2230134x18_hanspub.png" xlink:type="simple"/></inline-formula></p><p>最大程度上保留及提高患者的视功能 [<xref ref-type="bibr" rid="hanspub.19945-ref2">2</xref>] 。但由于PDR患者的增殖膜与视网膜粘连紧密，术中剥膜困难，易出现医源性裂孔及反复、大量的出血。不仅手术难度大、耗时长，术后视力提高也不明显。因此,如何消退视网膜新生血管膜，成为PDR治疗的关键。近年来，我们发现VEGF在PDR的发生发展中,尤其在新生血管形成中起着重要作用。VEGF作为一种促有丝分裂因子和血管生成因子，能特异性刺激血管内皮细胞，导致其分裂、增生、游走 [<xref ref-type="bibr" rid="hanspub.19945-ref3">3</xref>] ，并且通过增加血管的通透性、促进内皮细胞增殖 [<xref ref-type="bibr" rid="hanspub.19945-ref4">4</xref>] 、增加内皮细胞对葡萄糖的转运 [<xref ref-type="bibr" rid="hanspub.19945-ref5">5</xref>] 、改变细胞外基质、上调细胞间黏附分子１的基因表达等途径破坏血视网膜屏障，增加血管通透性，促使新生血管形成。因此，抗VEGF治疗受到越来越多的关注。在抗VEGF药物中，康柏西普是我国自主研发的一种重组融合蛋白，于2013年经我国CFDA 批准用于临床治疗。</p><p>本试验证实，抗VEGF治疗能为之后行PPV手术创造有力条件。术中我们发现：1) 试验组术中出血减少，这可能与康柏西普使新生血管膜收缩有关。2) 试验组新生血管膜更易剥除，这可能是由于康柏西普使血管通透性降低，改善视网膜充血，增强了视网膜的抗牵拉性，而且新生血管膜的收缩减少了与视网膜的粘附面积 [<xref ref-type="bibr" rid="hanspub.19945-ref6">6</xref>] 。3) 术中出血减少，可使术中视野清晰、电凝止血的频率降低、手术时间减少，医源性裂孔的发生率也有所减少。术后因复发玻璃体积血或视网膜脱离再次手术率统计学差异并不显著，与先前学者的研究不符，可能与本研究样本量过小有关。</p><p>然而，抗VEGF治疗的作用是暂时而非持续性的 [<xref ref-type="bibr" rid="hanspub.19945-ref7">7</xref>] 。有学者观察到抗VEGF治疗后，部分患者出现纤维组织增殖及TRD加重 [<xref ref-type="bibr" rid="hanspub.19945-ref8">8</xref>] 。因此玻璃体腔内注射康柏西普后行PPV手术时间的选择显得尤为重要。已有研究发现，抗VEGF治疗后3天内，纤维血管增殖膜的抑制效果并不明显，10天后观察到的抑制效果确切，而多于14天手术效果差于14天前 [<xref ref-type="bibr" rid="hanspub.19945-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.19945-ref10">10</xref>] 。本试验中，我们将手术时间定为玻璃体腔内注射康柏西普后6~8天，术中未发现有TRD加重的情况发生。</p><p>DME是导致糖尿病患者视力降低的主要原因之一。PPV可缓解部分黄斑区水肿，并提高大多数患者的视力 [<xref ref-type="bibr" rid="hanspub.19945-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.19945-ref12">12</xref>] 。其机制可能包括：PPV可去除玻璃体-视网膜界面的牵引力，复位脱离的视网膜，解除玻璃体对黄斑的机械性牵拉；PPV可去除致病因子，改善视网膜的缺氧状态等。有动物实验证实，猴子眼球内持续高水平的VEGF可导致黄斑水肿的发生 [<xref ref-type="bibr" rid="hanspub.19945-ref13">13</xref>] ，且患者眼内VEGF的表达水平与DME的严重程度呈正相关 [<xref ref-type="bibr" rid="hanspub.19945-ref14">14</xref>] 。康柏西普作为一种VEGF受体，可抑制新生血管的形成，降低血管通透性，减少血管渗漏，从而减轻黄斑水肿，提高患者的视力。本试验证实：对照组与试验组术后CFT较术前均有所降低，BCVA也均较术前有所提高。且试验组的疗效不管从CFT还是BCVA都优于对照组。ETDRS标准对数视力表精确度高，重复性好，因此国际上，ETDRS视力测试已经取代snellen和sloan视力测试成为全球视力测试标准 [<xref ref-type="bibr" rid="hanspub.19945-ref15">15</xref>] 。</p><p>综上所述，PDR围手术期玻璃体腔内注射康柏西普可有效地缩短手术时间，减少术中出血及术中术后并发症，增加手术的易行性，减少硅油填充率，同时可减轻黄斑水肿，使患者获得更好的最佳矫正视力，为临床治疗PDR开辟了一条新途径。但本试验样本数较少，随访时间较短，还需进一步增加样本量做更加深入地观察。</p></sec><sec id="s7"><title>文章引用</title><p>于梦丹,姜 涛,姜 靖,王云霄,李 廷,孙 哲,郑盼盼,全 威. 增殖性糖尿病视网膜病变围手术期玻璃体腔内注射康柏西普的疗效研究 Study on the Effect of Conbercept Intravitreal Injection for Proliferative Diabetic Retinopathy at Perioperative Period[J]. 眼科学, 2017, 06(01): 12-18. http://dx.doi.org/10.12677/HJO.2017.61003</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19945-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">乌云, 其其格, 杨亮单. 纯玻璃体切除术与联合超声乳化术治疗增生性糖尿病视网膜病变的疗效对比[J]. 中国实用医药, 2014(14): 3-6.</mixed-citation></ref><ref id="hanspub.19945-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">张祺, 冯劼, 程旭康, 等. 严重PDR玻璃体切除术和全视网膜光凝的视力对比[J]. 国际眼科杂志, 2012, 12(11): 2204-2205.</mixed-citation></ref><ref id="hanspub.19945-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">卢海. 增殖性糖尿病视网膜病变眼内组织纤溶酶原激活物及其抑制物的表达与VEGF表达的相关性研究[J]. 国际眼科杂志, 2007, 6(7): 501.</mixed-citation></ref><ref id="hanspub.19945-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">卢海, 张惠荣. 生长因子诱导的血管内皮细胞增殖作用的研究[J]. 眼科研究, 2001, 19(4): 297-300.</mixed-citation></ref><ref id="hanspub.19945-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sone, H., Deo, B.K. and Kumagai, A.K. (2000) Enhancement of Glucose Transport by Vascular Endothelial Growth Factor in Retinal Endothelial Cells. Investigative Ophthalmology &amp; Visual Science, 41, 1876-1884.</mixed-citation></ref><ref id="hanspub.19945-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chen, E. and Park, C.H. (2006) Use of Intravitreal Bevacizumab as Apreoperative Adjunct for Tractional Retinal Detachment Repair in Severe Proliferative Diabetic Retinopathy. Retina, 26, 699-700.  
&lt;br&gt;https://doi.org/10.1097/01.iae.0000225351.87205.69</mixed-citation></ref><ref id="hanspub.19945-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ip, M.S., Domalpally, A., Hopkins, J.J., et al. (2012) Long-Term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression. Arch Ophthalmol, 130, 1145-1152. &lt;br&gt;https://doi.org/10.1001/archophthalmol.2012.1043</mixed-citation></ref><ref id="hanspub.19945-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Van Geest, R.J., Lesnik-Oberstein, S.Y., Tan, H.S., et al. (2012) A Shift in the Balance of Vascular Endothelial Growth Factor and Connective Tissue Growth Factor by Bevacizumab Causes the Anglo Fibrotic Switch in Proliferative Diabetic Retinopathy. British Journal of Ophthalmology, 96, 587-590.</mixed-citation></ref><ref id="hanspub.19945-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">El-Sabagh, H.A., Abdelghaffar, W., Labib, A.M., et al. (2011) Preoperative Intravitreal Bevacizumab Use as an Adjuvant to Diabetic Vitrectomy: Histopathologic Findings and Clinical Implication. Ophthalmology, 118, 636-641.</mixed-citation></ref><ref id="hanspub.19945-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Gupta, A., Bansal, R., Gupta, V., et al. (2012) Six-Month Visual Outcome after Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy with or without a Single Preoperative Injection of Intravitreal Bevacizumab. International Ophthalmology, 32, 135-144. &lt;br&gt;https://doi.org/10.1007/s10792-012-9541-5</mixed-citation></ref><ref id="hanspub.19945-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ikeda, T., Sato, K., Katano, T., et al. (2000) Visual Acuity Following Pars Plana Itrectomy for Diabet Cystoidsmaculr Edema and Detached Posterior Hyaloids. Retina, 20, 220-222. &lt;br&gt;https://doi.org/10.1097/00006982-200002000-00023</mixed-citation></ref><ref id="hanspub.19945-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ikeda, T., Sato, K., Katano, T., et al. (1999) Vitrectomy for Cystoid Macular Oedema with Attached Posterior Hyaloidmembrane in Patients with Diabetes. British Journal of Ophthalmology, 83, 12-14.  
&lt;br&gt;https://doi.org/10.1136/bjo.83.1.12</mixed-citation></ref><ref id="hanspub.19945-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ozaki, H., Hayashi, H., Vinores, S.A., et al. (1997) Intravitreal Sustained Re-lease of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood-Retinal Barrier in Rabbits and Primates. Experimental Eye Research, 64, 505-517. &lt;br&gt;https://doi.org/10.1006/exer.1996.0239</mixed-citation></ref><ref id="hanspub.19945-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Funatsu, H., Noma, H., Mimura, T., et al. (2009) Association of Vitreous Inflammatory Factors with Diabetic Macular Edema. Ophthalmology, 116, 73-79.</mixed-citation></ref><ref id="hanspub.19945-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">程琳. ETDRS标准对数视力表视力测试[J]. 中华试验眼科杂志, 2011, 29(6): 574-575.</mixed-citation></ref></ref-list></back></article>